405 related articles for article (PubMed ID: 26627075)
41. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
42. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
Tong Y; Peranteau AJ; Nawas Z; Tyring SK
Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
44. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
45. Increase in antinuclear antibody levels through biologic treatment for psoriasis.
Miki M; Endo C; Naka Y; Fukuya Y; Kobayashi S; Kawashima M; Tsunemi Y
J Dermatol; 2019 Feb; 46(2):e50-e51. PubMed ID: 30051919
[No Abstract] [Full Text] [Related]
46. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
[TBL] [Abstract][Full Text] [Related]
47. Ustekinumab as therapy for psoriasis in a 2-year-old girl.
Min MS; Shroff A; Rose S; Lebwohl M; Guttman-Yassky E
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e109-e110. PubMed ID: 26377248
[No Abstract] [Full Text] [Related]
48. Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study.
Onderdijk AJ; Ijpma AS; Menting SP; Baerveldt EM; Prens EP
Br J Dermatol; 2015 Dec; 173(6):1536-9. PubMed ID: 26134667
[No Abstract] [Full Text] [Related]
49. Misunderstandings.
Feldman SR
J Dermatolog Treat; 2007; 18(1):4. PubMed ID: 17365258
[No Abstract] [Full Text] [Related]
50. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis.
Loget J; Plée J; Antonicelli F; Bernard P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e228-e230. PubMed ID: 27730667
[No Abstract] [Full Text] [Related]
51. Guselkumab (Tremfya) for psoriasis.
Med Lett Drugs Ther; 2017 Nov; 59(1533):179-180. PubMed ID: 29125591
[No Abstract] [Full Text] [Related]
52. Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.
Youn SW; Kim BR; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e298-e299. PubMed ID: 27976465
[No Abstract] [Full Text] [Related]
53. Combination therapy of infliximab and granulocyte/monocyte adsorption apheresis for refractory pustular psoriasis with psoriatic arthritis.
Fujisawa T; Moriya C; Shibuya Y; Kanoh H; Seishima M
Acta Derm Venereol; 2013 May; 93(3):364-5. PubMed ID: 23007291
[No Abstract] [Full Text] [Related]
54. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
Gniadecki R; Bang B; Sand C
Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
[No Abstract] [Full Text] [Related]
55. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
Nijsten T; Spuls PI
Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
[No Abstract] [Full Text] [Related]
56. Excellent response to ustekinumab in a 9-year-old girl with severe psoriasis.
González-Barreto RM; Rochet NM; Nevares-Pomales OW; Colón-Fontanez F
Pediatr Dermatol; 2018 Jan; 35(1):e76-e78. PubMed ID: 29205479
[TBL] [Abstract][Full Text] [Related]
57. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
Fujita Y; Shinkuma S; Nomura T; Shimizu H
Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
[No Abstract] [Full Text] [Related]
58. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
59. Tildrakizumab for treating psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
[TBL] [Abstract][Full Text] [Related]
60. Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept.
Brodmerkel C; Li K; Garcet S; Hayden K; Chiricozzi A; Novitskaya I; Fuentes-Duculan J; Suarez-Farinas M; Campbell K; Krueger JG
J Allergy Clin Immunol; 2019 May; 143(5):1965-1969. PubMed ID: 30703387
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
